Graft-vs-host disease following allogeneic hematopoietic cell transplantation.

  • Joseph A Pidala
  • Published 2011 in
    Cancer control : journal of the Moffitt Cancer…


BACKGROUND Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy with proven efficacy in the management of hematologic malignancies. However, it is complicated by the syndromes of acute and chronic graft-vs-host disease (GVHD). METHODS A narrative review is provided to summarize major biologic insights into the pathogenesis of these immune-mediated disorders, as well as advances in diagnosis, classification, prevention, management, and allied supportive care with the aim of providing essential understanding for clinicians with or without subspecialty experience in the field of blood and marrow transplantation. RESULTS Major scientific advances have contributed to enhanced understanding of the pathogenesis of these disorders, and clinical investigation has provided more effective preventive and therapeutic strategies for GVHD. However, since acute GVHD and chronic GVHD remain leading sources of transplantation-related morbidity and mortality, ongoing investigation is needed to develop new approaches to addressing these syndromes. CONCLUSIONS The major challenge for future investigation will be to capitalize on biologic insights in order to develop novel strategies for the prevention and therapy of acute and chronic GVHD that will address the current shortcomings in existing therapeutic approaches.

Citations per Year

508 Citations

Semantic Scholar estimates that this publication has 508 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Pidala2011GraftvshostDF, title={Graft-vs-host disease following allogeneic hematopoietic cell transplantation.}, author={Joseph A Pidala}, journal={Cancer control : journal of the Moffitt Cancer Center}, year={2011}, volume={18 4}, pages={268-76} }